The European Medicines Agency’s (EMA)) human medicines committee (CHMP) has recommended seven novel medicines for approval at ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of ...

Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Vertex Pharmaceuticals (VRTX) closed at $492.47 in the latest trading session, marking a +0.01% move from the prior day.

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

Analysts are piling on the praise for Vertex Pharmaceuticals, reaffirming bullish ratings even as the stock slightly fumbles ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US ...